WEIGHT MANAGEMENT PROGRAM FOR PATIENTS WITH DIABETES MELLITUS TYPE 2 TREATED WITH ORLISTAT – OUR EXPERIENCES
Abstract
Background. Obesity is an important risk factor in cardiovascular morbidity and mortality. Type 2 diabetic patients loose less weight than non-diabetics. Type 2 diabetic patients loose less weight than non-diabetics and thus a program for weight management in type 2 diabetic patients was established. Patients were treated with orlistat.
Methods. 31 patients were included having body mass index (BMI) above 27 kg/m2 not treated with acarbose or insulin. Four patients dropped out. In the first month individual counselling and education were offered. The goals of the program were weight loss and an improvement of glucose, lipid and blood pressure control. Six-month therapy with orlistat followed accompained with weekly group meetings.
Results. Clinically and statistically significant decreases that were relevated are as follows: body weight by 10.9 (standard deviation 6.8, p = 0.009) kg, fasting blood glucose by 2.1 (2.1, p = 0.0003) mmol/l, HbA1c by 1.4 (1.2, p = 0.0001)%, triglycerides by 0.52 (1.1, p = 0.049) mmol/l, systolic blood pressure by 12.1 (20.5, p = 0.028) mmHg, in patients with dyslipidemia total cholesterol by 0.4 (0.7, p = 0.032) mmol/l.
Conclusions. Treatment with orlistat, added upon intensive education program, can significantly decrease body weight and improve the whole profile of cardiovascular risk factors. During the program, patients gradually adapted their diet and behaviour. Therefore, this program could provide a solid ground for lifelong lifestyle changes of obese type 2 diabetic patients.
Downloads
References
McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J 1999; 138: S366–75.
WHO. Obesity; preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva: WHO, 1998.
Colditz GA, Willett WC, Stampfer MJ et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501–13.
Brown CD, Higgins M, Donato KA et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8: 605–19.
Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to high blood cholesterol levels in white American men. Arch Intern Med 1993; 153: 1093–103.
Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987; 10: 563–6.
Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000; 248: 245–54.
Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance and improved cardiovascular factors after 2 years treatment with orlistat for obesity. Europe Orlistat Obesity Study Group. Obes Res 2000; 8: 49–61.
Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 y. Am J Epidemiol 1995; 141: 1128–41.
Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med 1990; 7: 228–33.
Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study: a 9-year update of randomized controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med 1996; 124: 136–45.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
National Institutes of Health. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III). National Cholesterol Education Program. USA, National Heart, Lung, and Blood Institute. NIH Publication No. 01-3670, 2001.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
